Modulation of p53 and c-myc in DMBA-induced mammary tumors by oral glutamine

Nutrition and Cancer

Volumn 54, Issue 2, 2006, Pages 263-273

  Todorova, Valentina K ^a,c   Kaufmann, Yihong ^b   Luo, Shaoke ^a   Klimberg, V Suzanne ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AES 14; CYCLIN DEPENDENT KINASE INHIBITOR 1; DIMETHYLBENZ[A]ANTHRACENE; DNA; GLUTAMINE; GLUTATHIONE; MESSENGER RNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DOWN REGULATION; ENZYME INHIBITION; EXON; FEMALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RAT; RAT STRAIN; RNA ANALYSIS; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADMINISTRATION, ORAL; ANIMALS; CARCINOGENS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINE; GLUTATHIONE; MAMMARY NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-MYC; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748132632     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5402_13     Document Type: Article

References (65)

1. Oehler R and Roth E: Regulative capacity of glutamine. Curr Opinion in Clin Nutr Metabol Care 6, 277-282, 2003.
2. Klaunig JE and Kamendulis LM: The role of oxidative stress in carcinogenesis. Annual Review Pharmacol Toxicol 44, 239-267, 2004.
3. Jones DP: Redox potential of GSH/GSSG couple: assay and biological significance. Methods Enzymol 348, 93-112, 2002.
4. Arrigo AP: Gene expression and the thiol redox state. Free Radic Biol Med 27, 936-944, 1999.
5. Nkabyo YS, Ziegler TR, Gu LH, Watson WH, and Jones DP: Glutathione and thioredoxin redox during differentiation in human colon epithelial (Caco-2) cells. Am J Physiol Gastrointest Liver Physiol 283, G1352-G1359, 2002.
6. Atzori L, Dypbukt JM, Sundqvist K, Cotgreave I, Edman CC, et al.: Growth-associated modifications of low-molecular-weight thiols and protein sulfhydryls in human bronchial fibroblast. J Cell Physiol 143, 165-171, 1989.
7. Jones DP: Redox potential of GSH/GSSG couple: assay and biological significance. Methods Enzymol 348, 93-112, 2002.
8. Chandra J, Samali A, and Orrenius S: Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 29, 323-333, 2000.
9. Voehringer DW: Bcl-2 and glutathione alterations in cellular redox state that regulate apoptotic sensitivity. Free Radic Biol Med 27, 945-950, 1999.
10. Arrigo AP: Gene expression and the thiol redox state. Free Radic Biol Med 27, 936-944, 1999.
11. Achanta G and Huang P: Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res 64, 6233-6239, 2004.
12. Hall AG: The role of glutathione in the regulation of apoptosis. Eur J of Clin Investig 29, 238-245, 1999.
13. Selivanova G: p53: fighting cancer. Curr Cancer Drug Targets 4, 385-402, 2004.
14. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, et al.: p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810, 1994.
15. Lowe SW, Ruley HE, Jacks T, and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967, 1993.
16. Wolf CR, Lewis AD, Carmichael J, Adams DJ, Allan SG, et al.: The rule of glutathione in determining the response of normal and tumor cells to anticancer drugs. Biochem Soc Trans 15, 728-730, 1987.
17. Arrick B and Nathan C: SH metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 44, 4224-4232, 1984.
18. Schroder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC, et al.: Glutathione and drug resistance. Cancer Invest 14, 158-168, 1996.
19. Roth E, Oehler R, Manhart N, Exner R, Wessner B, et al.: Regulative potential of glutamine-relation to glutathione metabolism. Nutrition 18, 217-221, 2002.
20. Wang T, Chen X, Scheeter RL, Baruehel S, Alaoui-Lamali M, et al.: Modulation of glutathione by a cysteine pro-drug enhances in vivo tumor response. J Pharamacol Exp Therap 276, 1169-1173, 1996.
21. Johnson AT, Kaufmann YC, Luo S, Todorova V, and Klimberg VS: Effect of glutamine on glutathione. IGF-1, and TGF-beta 1. J Surg Res 111, 222-228, 2003.
22. Todorova VK, Kaufmann Y, Luo S, Harms SA, Babb KB, et al.: Glutamine supplementation reduces glutathione levels and stimulates apoptosis in DMBA-induced mammary tumors. Breast Cancer Res Treat 88, 247-256, 2004.
23. Cao Y, Feng Z, Hoos A, and Klimberg VS: Glutamine enhances gut glutathione production. J Parent Ent Nutr 22, 224-227, 1998.
24. Klimberg VS, Nwokedi E, Hutchins LH, Pappas AP, Lang NP, et al.: Does glutamine facilitate chemotherapy while reducing its toxicity? Surg Forum 42, 16-18, 1991.
25. Klimberg VS, Souba WW, Salloum RM, Plumley DA, Cohen FS, et al.: Glutamine-enriched diets support muscle glutamine metabolism without stimulating tumor growth. J Surg Res 48, 319-323, 1990.
26. Russo J and Russo IH: Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 39, 7-20, 1996
27. Fukunishi R: Studies on tumor induction in rats with 7, 12-DMBA with special references to the morphogenesis and fine structural changes in the target organs. Acta Pathol Jpn 18, 51-72, 1968.
28. Costa I, Solanas M, and Escrich E: Histopathologic characterization of mammary neoplastic lesions induced with 7,12 dimethylbenz(alpha)anthracene in the rat: a comparative analysis with human breast tumors. Arch Pathol Lab Med 126, 915-927, 2002.
29. Kito K, Kihana T, Sugita A, Murao S, Akehi S, et al.: Incidence of p53 and Ha-ras gene mutations in chemically induced rat mammary carcinomas. Mol Carcinog 17, 78-83, 1996.
30. Jerry DJ, Butel JS, Donehower LA, Paulson EJ, Cochran C, et al.: Infrequent p53 mutations in 7,12-dimethylbenz(a)anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice. Mol Carcinog 9, 175-183, 1994.
31. Todorova VK, Luo S, Kaufmann Y, Babb K, Harms SA, et al.: Oral glutamine supplementation inhibits P13K/Akt signaling pathway in experimental breast cancer. J Parent Ent Nutr 27, 404-410, 2003.
32. Marone M, Mozzetti S, Ritis DD, Pierelli L, and Scambia G: Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample. Biol Proced Online 3, 19-25, 2001.
33. Barabas E, Nagy K, Varkonyi V, and Horvath A: Comparison of the quantitative competitive and semiquantitative RT-PCR methods for the determination of interferon-gamma mRNA levels in AIDS-free HIV-infected individuals. Braz J Med Biol Res 34, 1271-1275, 2001.
34. Kaufmann Y, Luo S, Johnson A, Babb K, and Klimberg VS: Timing of oral glutamine on DMBA-induced tumorigenesis. J Surg Res 111, 158-165, 2003.
35. Steegenga WT, van der Eb AJ, and Jochemsen AG: How phosphorylation regulates the activity of p53. J Mol Biol 263, 103-113, 1996.
36. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, et al.: Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18, 1805-1814, 1999.
37. Chehab NH, Malikzay A, Stavridi ES, and Halazonetis TD: Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 96, 13777-13782, 1999.
38. Jimenez C, Hernandez C, Pimentel B, and Carrera AC: The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J Biol Chem 277, 41556-41562, 2002.
39. Maeip S, Igarashi M, Berggren P, Yu J, Lee SW, et al.: Influence of induced reactive oxygen species in p53-mediated cell late decisions. Mol Cell Biol 23, 8576-8585, 2003.
40. Lomaestro BM and Malone M: Glutathionein health and disease: pharmacotherapeutic issues. The Ann Pharmacother 29, 1263-1273, 1995.
41. Kannan K, Amariglio N, and Rechavi GSL: DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20, 2225-2234, 2001.
42. Schroder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC, et al.: Glutathione and drug resistance. Cancer Invest 14, 158-168, 1996.
43. El-Deiry WS, Tukino T, Velculescu VE, Levy DB, Parsons R, et al.: Waf1, a potential mediator of p53 tumor suppression. Cell 75, 817-825, 1993.
44. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, et al.: p53-dependent and independent expression of p21 during cell growth, differentation, and DNA damage. Genes Dev 9, 935-944, 1995.
45. Stamholic V, MacPherson D, Sas D, Lin Y, Snow B, et al.: Regulation of PTEN transcription by p53. Mol Cell 8, 317-325, 2001.
46. Chung MJ, Jung SH, Lee BJ, Kang MJ, and Lee DG: Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int 54, 10-15, 2004.
47. Zhang R, and Wang H: MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des 6, 393-416, 2002.
48. Haupt Y, Maya R, Kazaz A, and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299, 1997.
49. Kubbutat MH, Jones SN, and Vousden KH: Regulation of p53 stability by Mdm2. Nature 387, 299-303, 1997.
50. Moll UM and Petrenko O: The MDM2-p53 interaction. Mol Cancer Res 1, 1001-1008, 2003.
51. Ohlsson C, Kley N, Werner H, and LeRoith D: p53 regulates insulin-like growth factor-1 (IGF-1) receptor expression and IGF-1-induced tyrosine phosphorylation in an osteosarcoma cell line:interaction between p53 and Spl. Endocrinology 139, 1101-1107, 1998.
52. Cullen KJ, Allison A, Martire I, Ellis M, and Singer C: Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 22, 21-9, 1992.
53. Butler AA, Yakar S, Gewolb IH, Karas M, Okuho Y, et al.: Insulin-like growth factor-1 receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol 121, 19-26, 1998.
54. Surmacz E, Guvakova MA, Nolan MK, Nicosia RF, and Sciacca L: Type 1 insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 47, 255-267, 1998.
55. Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, et al.: MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 10, 499-507, 2004.
56. Watson PH, Safneck JR, Le K, Dubik D, and Shiu RP: Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst 85, 902-907, 1993.
57. Naidu R, Wahab NA, Yadav M, and Kutty MK: Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med 9, 189-196, 2002.
58. Hulit J, Di Vizio D, and Pestell RG: Inducible transgenics: New lessons on events governing the induction and commitment in mammary tumorigenesis. Breast Cancer Res 3, 209-212, 2001.
59. Alevizopoulos K, Vladi J, Hennecke S, and Amali B: Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J 16, 5322-5333, 1997.
60. Lutz W, Leon J, and Eilers M: Contributions of Myc to tumorigenesis. Biochim Biophys Acta 1602, 61-71, 2002.
61. Biroccio A, Benassi B, Filomeni G, Amodei S, Marchini S, et al.: Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells. J Biol Chem 277, 43763-43770, 2002.
62. Carretero J, Obrador E, Pellicer J, Pascual A, and Estrela J: Mitochondrial glutathione depletion by glutamine in growing tumor cells. Free Radic Biol Med 29, 913-923, 2000.
63. Klimberg VS and McClellan JL: Glutamine, cancer, and its therapy. Am J Surg 172, 418-424, 1996.
64. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, and Corey B: Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29, 501-513, 2003.
65. Rouse K, Nwokedi E, Woodliff J, Epstein J, and Klimberg VS: Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann Surg 221, 420-426, 1995.